logo

HRTX

Heron Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

HRTX fundamentals

Heron Therapeutics (HRTX) released its earnings on Nov 4, 2025: revenue was 38.20M (YoY +16.43%), missed estimates; EPS was -0.1 (YoY -233.33%), missed estimates.
Revenue / YoY
38.20M
+16.43%
EPS / YoY
-0.1
-233.33%
Report date
Nov 4, 2025
HRTX Earnings Call Summary for Q3,2025
  • Acute Care Surge: ZYNRELEF +49% YoY, APONVIE +173% YoY, Q3 acute care revenue $12.3M
  • J-code Win: ZYNRELEF billing clarity drives 17% Oct unit growth
  • CINVANTI Resilience: Stable at $24M despite competitive pressure
  • 2027 PFS Launch: Simplified delivery system targets late 2027 approval
  • Cash Position: $55.5M post-financing, debt extinguishment costs $11.3M
EPS
Revenue

Revenue & Expenses

HRTX has released its 2025 Q3 earnings report, with revenue of 38.21M, reflecting a YoY change of 16.47%, and net profit of -17.50M, showing a YoY change of -260.87%. The Sankey diagram below clearly presents HRTX's revenue sources and cost distribution.

Key Indicators

Heron Therapeutics (HRTX) key financial stats and ratios, covering profitability, financial health, and leverage.
Heron Therapeutics (HRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Heron Therapeutics (HRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Heron Therapeutics (HRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Heron Therapeutics (HRTX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Heron Therapeutics (HRTX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield